Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Globus Medical To Merge With NuVasive In $3.1Bn All-Stock Deal Analysts Foresee Challenges

Executive Summary

Analysts from Piper Sandler and BTIG noted that the proposed merger between Globus Medical and NuVasive raises concerns about cultural fit, approach to commercialization and profitability, as well as anti-trust issues.

You may also be interested in...



Becton Dickinson Receives FDA Clearance For Vaginal Panel To Detect Vaginitis

BD said its newly FDA-cleared Vaginal Panel can detect three most common infectious causes of vaginitis with a single swab, reducing the need for repeat testing.

Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival

Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.

Digital Health Roundup: Omar Ishrak’s SPAC; AI In Dermatology, IVF, Imaging; Wellness Apps And Trust

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights how Alife Health is using its AI-based platform for IVF to increase chances for successful pregnancies while Barnaby Pickering discusses how AI Medical Technology is using AI to detect melanoma. Reed Miller talks about weight-loss device maker Allurion Technologies’ signed SPAC deal.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel